参考文献/References:
[1] Higashi Y,Noma K,Yoshizumi M,et al. Oxidative stress and endothelial function in cardiovascular diseases[J]. Circ J,2009,73:411-418.
[2] Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function– from research into clinical practice[J]. Circulation,2012,126(6):753-767.
[3] Arrebola-Moreno AL, Laclaustra M, Kaski JC. Noninvasive assessment of endothelial function in clinical practice[J]. Rev Esp Cardiol(Engl Ed),2012,65(1):80-90.
[4] Tousoulis D, Simopoulou C, Papageorgiou N, et al. Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches[J]. Pharmacol Ther,2014,144(3):253-267.
[5] Matsuzawa Y, Lerman A. Endothelial dysfunction and coronary artery disease:assessment,prognosis,and treatment[J]. Coron Artery Dis,2014,25(8):713-724.
[6] Flammer AJ, Lüscher TF. Three decades of endothelium research:from the detection of nitric oxide to the everyday implementation of endothelial function measurements in cardiovascular diseases[J]. Swiss Med Wkly, 2010,140:w13122.
[7] Flammer AJ, Vo NTT, Ledergerber B, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons:randomised controlled trial[J]. Heart, 2009,95:385-390.
[8] Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse event[J]. Eur Heart J,2010,31:1142-1148.
[9] Leung DY, Leung M. Non-invasive/invasive imaging:significance and assessment of coronary microvascular dysfunction[J]. Heart,2011,97:587-595.
[10] Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries[J]. N Engl J Med,1986,315:1046-1051.
[11] Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease[J]. Circulation,2000,101:1899-1906.
[12] Leung DY, Leung M. Non-invasive/invasive imaging:significance and assessment of coronary microvascular dysfunction [J]. Heart,2011,97:587-595.
[13] Panza JA, Quyyumi AA, Brush JE Jr, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension[J]. N Engl J Med,1990,323:22-27.
[14] Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators[J]. Hypertension,1995,25:918-923.
[15] Soga J, Noma K, Hata T, et al. Rho-associated kinase activity, endothelial function, and cardiovascular risk factors[J]. Arterioscler Thromb Vasc Biol,2011,31:2353-2359.
[16] Iwamoto Y, Maruhashi T, Fujii Y, et al. Intima-media thickness of brachial artery, vascular function, and cardiovascular risk factors[J]. Arterioscler Thromb Vasc Biol,2012,32:2295-2303.
[17] Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J]. Lancet,1992,340:1111-1115.
[18] Halcox JPJ, Donald AE, Ellins E, et al. Endothelial function predicts progression of carotid intima-media thickness[J]. Circulation,2009,119:1005-1012.
[19] Karatzis EN, Ikonomidis I, Vamvakou GD, et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation[J]. Am J Cardiol,2006,98:1424-1428.
[20] Thijssen DHJ, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans:a methodological and physiological guideline[J]. Am J Physiol Heart Circ Physiol,2011,300:H2-H12.
[21] Higashi Y. Assessment of endothelial function history, methodological aspects, and clinical perspectives[J]. Int Heart J,2015,56:125-134.
[22] Reisner Y, Lusky R, Shay-El Y, et al. Reproducibility of endothelial function and arterial stiffness assessed using finger peripheral arterial tonometry[J]. Eur Heart J,2008,Suppl 29:491.
[23] Hamburg NM, Palmisano J, Larson MG, et al. Relation of brachial and digital measures of vascular function in the community: the Framingham heart study[J]. Hypertension,2011,57:390-396.
[24] Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study[J]. Circulation,2008,117:2467-2474.
[25] Patvardhan EA, Heffernan KS. Assessment of vascular endothelial function with peripheral arterial tonometry information at your fingertips?[J]. Cardiol Rev,2010,18:20-28.
[26] Idei N, Ukawa T, Kajikawa M, et al. A novel noninvasive and simple method for assessment of endothelial function:enclosed zone flow-mediated vasodilation(ezFMD)using an oscillation amplitude measurement[J]. Atherosclerosis,2013,229(2):324-330.
[27] Idei N, Ukawa T, Hata T, et al. A novel noninvasive and simple method for assessment of endothelial function:enclosed zone flow-mediated vasodilation(ezFMD)using an oscillation amplitude measurement[J]. Atherosclerosis,2013,229:324-330.
[28] Mocco J, Choudhri TF, Mack WJ, et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis[J]. Neurosurgery,2001,48:718-721.
[29] Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction[J]. Circulation,2000,101:948-954.
[30] Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction[J]. Circulation,2002,106:653-658.
[31] Akiyama E, Sugiyama S, Matsuzawa Y, et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction[J].J Am Coll Cardiol,2012,60:1778-1786.
[32] Kato T, Umeda A, Miyagawa K, et al. Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function[J]. Hypertens Res,2014,37:655-658.
[33] Maruhashi T, Soga J, Fujimura N, et al. Relationship between flow-mediated vasodilatation and cardiovascular risk factors in a large community-based study[J]. Heart,2013,99:1837-1842.
相似文献/References:
[1]胥雪莲,何川.前蛋白转化酶枯草溶菌素9与动脉粥样硬化[J].心血管病学进展,2016,(1):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
XU Xuelian,HE Chuan.Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(4):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
[2]吴文芳,赵新湘,闫东.颈动脉斑块的核磁共振成像检测在冠心病中研究及应用进展[J].心血管病学进展,2016,(1):91.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.024]
WU Wenfang,ZHAO Xinxiang,YAN Dong.Magnetic Resonance Imaging Detection of Carotid Artery Plaque in
Coronary Artery Disease and Its Application[J].Advances in Cardiovascular Diseases,2016,(4):91.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.024]
[3]阎萌,田芳,综述,等.程序性坏死与动脉粥样硬化[J].心血管病学进展,2016,(2):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
YAN Meng,TIAN Fang,TIAN Ye.Necroptosis and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(4):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
[4]许利冬,综述,李为民,等.左主干解剖形态与左冠状动脉粥样硬化研究新进展[J].心血管病学进展,2016,(2):173.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.020]
XU Lidong,LI Weimin.New Progress Between Left Main Coronary Anatomy and Left Coronary
Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(4):173.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.020]
[5]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated
Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(4):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[6]蔡鹏,综述,王旭开,等.胰岛素清除率下降机制及其对大血管损伤作用的研究进展[J].心血管病学进展,2016,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.020]
CAI Peng,WANG Xukai.Mechanism and Large Vascular Injury Effect of Insulin Clearance Decrease[J].Advances in Cardiovascular Diseases,2016,(4):292.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.020]
[7]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(4):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[8]于洋杰 谢坤 高秀芳 施海明 李勇.非高密度脂蛋白胆固醇可以替代低密度脂蛋白胆固醇吗？[J].心血管病学进展,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Yangjie,XIE Kun,GAO Xiufang,et al.Can LDL-C be Replaced by non-HDL-C[J].Advances in Cardiovascular Diseases,2021,(4):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[9]于洋杰 谢坤 施海明.血管生成素样蛋白3抑制剂研究进展[J].心血管病学进展,2021,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.013]
YU Yangjie,XIE Kun,SHI Haiming.Angiopoietin-like Protein 3 Inhibitors[J].Advances in Cardiovascular Diseases,2021,(4):530.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.013]
[10]许晓宇 唐炯 郑甲林.PCSK9对血管内皮功能影响的研究进展[J].心血管病学进展,2023,(6):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
XU Xiaoyu,TANG Jiong,ZHENG Jialin.Research Progress on the Effects of PCSK9 on Vascular Endothelial Function[J].Advances in Cardiovascular Diseases,2023,(4):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]